Navigation Links
AUA Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer
Date:3/3/2010

LINTHICUM, Md., March 3 /PRNewswire/ -- Today, the American Cancer Society issued its new Guideline for the Early Detection of Prostate Cancer. The American Urological Association (AUA), which represents more than 16,000 urologists and urologic health professionals worldwide, issued the following statement in response to the new ACS document. The statement is attributable to AUA President Anton J. Bueschen, MD.

"The American Urological Association (AUA) today applauds the American Cancer Society (ACS) for its new guidance statement on prostate cancer detection. We concur that informed consent – including a discussion between physician and patient about the risks and benefits of testing – is a key part of one's decision to be tested for prostate cancer. It is equally necessary that patients receive reliable information from culturally appropriate sources.

However, the new ACS statement may not fully characterize the potential benefits of an individualized approach to assessing risk in men considering the risk and benefits of early detection strategies and may cause significant confusion for patients. The AUA feels there is no single PSA standard that applies to all men, nor should there be. Part of informed consent is giving patients as much information about their personal risk as is available. Applying population-based cut points while ignoring other individual risk factors (such as age, ethnicity, family history, previous biopsy characteristics, etc.) may not give a patient the most optimal assessment of his risk, including the risk of high grade disease.

Prostate cancer testing is an individual decision that patients should make together with their doctor. The AUA believes that all men, with a life expectancy of 10 years or more, should have a baseline PSA test at the age of 40. Physicians should determine rescreening intervals for each patient based on PSA (and, on occasion on its change over time). Likewise, the decision to proceed to prostate biopsy should be based not only on elevated PSA and/or abnormal DRE results, but should take into account multiple factors including free and total PSA, patient age, PSA velocity, PSA density, family history, ethnicity, prior biopsy history and comorbidities. Although prostate cancer risk correlates with serum PSA, there is no PSA value below which a man may be reassured that he does not have biopsy detectable prostate cancer.

The AUA is in full agreement with the ACS that current early detection strategies need to be refined and better validated.  It is hoped that new biomarkers will be identified which better distinguish between indolent and aggressive prostate cancer, sparing the former from unnecessary testing and giving the latter a better chance of survival."

In April 2009, the AUA issued its new Best Practice Statement on Prostate-Specific Antigen, which can be viewed here. www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.

    
    
    Contact:  Wendy Isett, AUA          Victoria Fort
              Communications Manager    Zeno Group
              410-977-4770,             202-361-0445,
              wisett@AUAnet.org         Victoria.Fort@zenogroup.com

SOURCE American Urological Association

Back to top
'/>"/>
SOURCE American Urological Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. American Red Cross Responds Internationally and at Home to Chile Quake
2. FriendsofWater.com Responds to the National Acadamy of Sciences Report that Millions of Americans Get Sick Yearly from Contaminated Water
3. Miami Based Non-Profit Responds to Congress's Call for Leadership
4. CRN Responds to Introduction of New Dietary Supplement Legislation
5. FRC Responds to New Study Showing Abstinence Education is Most Effective
6. Coachella Valley Responds to Haiti Disaster with $1-million in Aid
7. USAIDs Global Health Bureau Responds to Haitis Medical Crisis
8. Vitamin Angels Responds to Haiti Disaster
9. CRN Responds to Ginkgo Biloba Study
10. QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators
11. Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Salus Telehealth, Inc. ... company’s VideoMedicine mobile platform has launched Quick Care, a new service offering on-demand ... Care provides patients with the option to request and begin a consultation with ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to 78,000 ... 25,000 of them will be malignant.(1) As research into precision medicine continues, both ... model in the diagnosis and treatment of brain tumors. Healthcare facilities that are ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... individuals with HIV because it is not known to have significant interactions with ... effects to both lower cholesterol levels and dampen inflammation in the bloodstream. , ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... to become familiar. This makes it difficult for lab operators and management to ... methodology to help them identify wasteful or unnecessary actions. , Created with ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “Reflections of God’s ... God. “Reflections of God’s Work” is the creation of published author, Jerri Broglin, a ... comfort. , “I believe this a great eye-opener for those searching for answers, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology: